Systematic Review and Meta‐Analysis of Real‐World Studies Evaluating Rivaroxaban for Cancer‐Associated Venous Thrombosis

Introduction While not designated as guideline‐recommended first‐line anticoagulation therapy, about one in five patients in the United States receive rivaroxaban for the treatment of cancer‐associated venous thrombosis (CAT). Methods A systematic review and meta‐analysis were performed to evaluate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacotherapy 2018-06, Vol.38 (6), p.610-618
Hauptverfasser:	Martinez, Brandon K., Sheth, Jit, Patel, Nishi, Baker, William L., Coleman, Craig I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticoagulants anticoagulation Bleeding Cancer cancer‐associated thrombosis Clinical trials Factor Xa Inhibitors - therapeutic use Health risk assessment Humans Incidence Meta-analysis Mortality Neoplasms - complications Patients rivaroxaban Rivaroxaban - adverse effects Rivaroxaban - therapeutic use Systematic review Thromboembolism Thrombosis Venous Thromboembolism - drug therapy Venous Thromboembolism - epidemiology Venous Thromboembolism - etiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!